<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02686918</url>
  </required_header>
  <id_info>
    <org_study_id>2016-01</org_study_id>
    <nct_id>NCT02686918</nct_id>
  </id_info>
  <brief_title>Feasibility Assessment of a Patients Follow-up Visit Receiving Trastuzumab Subcutaneous by Advanced Practice Nurse</brief_title>
  <acronym>TIPA</acronym>
  <official_title>Feasibility Assessment of a Patients Follow-up Visit Receiving Trastuzumab Subcutaneous by Advanced Practice Nurse - TIPA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Cancérologie de la Loire</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de Cancérologie de la Loire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main of this study is to assess the feasibility of a patients follow-up visit receiving
      trastuzumab subcutaneous by Advanced Practice Nurse.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of consultation requiring a medical advice between IPA and oncologist</measure>
    <time_frame>1 year</time_frame>
    <description>Estimate the correlation between the IPA and the oncologist about whether or not a medical opinion during the consultation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of consultations delegated to the IPA</measure>
    <time_frame>1 year</time_frame>
    <description>The oncologist estimate the percentage of consultations can be delegated to the IPA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician satisfaction questionnaire</measure>
    <time_frame>1 year</time_frame>
    <description>Physician satisfaction questionnaire of the delegation of his consultations to the IPA</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>consultation by Advanced Practice Nurse.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During consultations, patients will be seen successively by Advanced Practice Nurse and referent oncologist.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Advanced Practice Nurse consultation</intervention_name>
    <arm_group_label>consultation by Advanced Practice Nurse.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient care at the Cancer Institute Lucien Neuwirth

          -  Patient aged over 18 years

          -  Patient with breast cancer overexpressing HER2 adjuvant

          -  Patient having finished their chemotherapy treatment with IV followed the oncologist
             day hospital

          -  Patient under Trastzumab subcutaneously

          -  Patient affiliated or entitled to a social security scheme (mandatory requirement for
             all studies)

        Exclusion Criteria:

          -  Refusal to participate, most patient protected under guardianship.

          -  Patient in inability to understand the course of the study

          -  Patient with documented history of cognitive or psychiatric disorders.

          -  Patients pregnant or lactating

          -  Patients under guardianship or curatorship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mathieu ORIOL, MD</last_name>
    <phone>04 77 91 70 71</phone>
    <email>mathieu.oriol@icloire.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cécile MIGALA, IPA</last_name>
    <email>cecile.migala@icloire.fr</email>
  </overall_contact_backup>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2016</study_first_submitted>
  <study_first_submitted_qc>February 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2016</study_first_posted>
  <last_update_submitted>February 16, 2016</last_update_submitted>
  <last_update_submitted_qc>February 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

